Project: Targeted Treatment of Portal Hypertension in EVH Liver Patients

Acronym DeLiver (Reference Number: 10844)
Duration 01/04/2017
Project Topic DeLiver aims to develop the first targeted treatment for liver patients prone to die from massive bleeding caused by Portal Hypertension (PH). The approach consists of delivering an effective amount of a kinase inhibitor to hepatic stellate cells (HSC) using the proprietary Lx linker and HSC specific nanobodies (called LxL1). DeLiver is a pre-clinical study permitting assessment of LxL1 in a first-in-man (FIM) investigator initiated trial (IIT) for a yet unmet medical condition
Network Eurostars 2
Call Eurostars Cut-Off 6

Project partner

Number Name Role Country
1 LinXis B.V. Coordinator Netherlands
2 Nuvisan Partner Germany
3 Universität Bonn Partner Germany